Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer

Exclusion criteria

• ✕. During Screening period and treatment period, the main target for lesions has been given radiation;
• ✕. The body has metal material, including a metal JieYuHuan/support/operation fixed material within;
• ✕. Existing cerebrovascular diseases and central nervous system tumors, including metastatic carcinoma;
• ✕. Patients with recent or ongoing gastrointestinal bleed may not be transfused to reach the entry hemoglobin of 8.5 g/dL Physicians should ensure patients requiring transfusion prior to registration do not have an occult or clinically apparent gastrointestinal bleed No history of bleeding diathesis;
• ✕. No significant history of cardiac disease, including any of the following: NYHA class III-IV congestive heart failure Myocardial infarction within the past 6 months Cardiac arrhythmias requiring anti-arrhythmic therapy (other than beta blockers or digoxin) LVEF \< 45% (or below the normal limit at the individual institution) by scintigraphy (MUGA or myocardial scintigram) History of hypertension allowed provided it is well controlled (i.e., BP \< 140/90 mm Hg) on a regimen of anti-hypertensive therapy
• ✕. Other prior adjuvant therapy is allowed provided it was completed \> 6 months ago AND there is documented recurrence of NSCLC
• ✕. No prior systemic therapy for metastatic disease At least 4 weeks since prior locoregional therapy (e.g., embolization, chemoembolization \[except with doxorubicin hydrochloride\], radiotherapy, or radioactive microspheres)
• ✕. No prior local therapy for the target lesion unless the target lesion located within the field of local therapy has shown ≥ 25% increase in size since last treatment